AML1-ETO binding sites in patient AML CD34⁺ cells with t(8;21). (A) Overview of the ITGB2 and OGG1 AML1-ETO binding sites. Two cell lines (SKNO-1 and Kasumi-1) and blasts of 3 AML patients with t(8;21) were used in ChIP-seq experiments using a specific antibody that could recognize AML1-ETO (AE). (B) Venn diagram representing the overlap of binding sites detected in patients AML cells with t(8; 21); n = 3. (C) Overview of the SPI1 AML1-ETO binding site. A blast from one AML patient with t(8;21) was used in ChIP-seq experiments using a specific antibody that could recognize ERG and compared with the ChIP-seq results of AML1-ETO (AE) in 3 patient blasts with t(8;21). (D) Venn diagram representing the overlap of the 2898 common AML1-ETO binding sites detected in 3 patients with t(8;21) and ERG binding sites detected in one patient (pz12) with t(8;21).